Cargando…

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

Detalles Bibliográficos
Autores principales:	Harrington, Patrick, Doores, Katie J., Saunders, Jamie, de Lord, Marc, Saha, Chandan, Lechmere, Thomas, Khan, Hataf, Lam, Ho Pui Jeff, Reilly, Amy O’, Woodley, Claire, Asirvatham, Susan, Dillon, Richard, Curto-Garcia, Natalia, Sullivan, Jennifer O’, Kordasti, Shahram, Raj, Kavita, Malim, Michael H., Radia, Deepti, McLornan, Donal, Harrison, Claire, de Lavallade, Hugues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024068/ https://www.ncbi.nlm.nih.gov/pubmed/35459222 http://dx.doi.org/10.1038/s41408-022-00651-3

Ejemplares similares

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
por: Harrington, Patrick, et al.
Publicado: (2021)

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders
por: Harrington, Patrick, et al.
Publicado: (2022)

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center
por: Khan, Alesia, et al.
Publicado: (2021)

P990: T CELL RESPONSE AND OMICRON VARIANT NEUTRALISATION FOLLOWING VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH CHRONIC MYELOID DISORDERS
por: Harrington, P., et al.
Publicado: (2022)

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021
por: Saunders, Jamie, et al.
Publicado: (2021)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
por: Okikiolu, Jumoke, et al.
Publicado: (2022)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
por: Harrington, Patrick, et al.
Publicado: (2023)

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?
por: McLornan, Donal, et al.
Publicado: (2013)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms
por: Contreras Castillo, Stephania, et al.
Publicado: (2021)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony, Sarah, et al.
Publicado: (2020)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
por: Tremblay, Douglas, et al.
Publicado: (2019)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis
por: te Linde, Elsemieke, et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Urosepsis and the urologist!
por: Ryan, James, et al.
Publicado: (2021)

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
por: Gupta, Vikas, et al.
Publicado: (2020)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018)

Intravesical recurrence of chromophobe renal cell carcinoma
por: Kelly, Niall P., et al.
Publicado: (2023)

Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study
por: Sheth, Vipul, et al.
Publicado: (2021)

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis
por: Buks, Ralfs, et al.
Publicado: (2021)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
por: Seow, Jeffrey, et al.
Publicado: (2022)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms
por: Cortés, Alicia Arenas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s2822dsi4b5fmkkdc3dd2p38up